Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
297. lappuse
... remove stopper . Not for intravenous nor intramuscular use . Do not use after expiration date shown on outside wrapper or container . Do not use if drug has become viscous or if In addition to the above warnings , the following ...
... remove stopper . Not for intravenous nor intramuscular use . Do not use after expiration date shown on outside wrapper or container . Do not use if drug has become viscous or if In addition to the above warnings , the following ...
345. lappuse
... remove any of such drug from such es- tablishment unless it complies with section 502 ( 1 ) of the act or the certifi- cation requirements of section 512 ( n ) of the act or is so exempt or is returned to him for labeling . When the ...
... remove any of such drug from such es- tablishment unless it complies with section 502 ( 1 ) of the act or the certifi- cation requirements of section 512 ( n ) of the act or is so exempt or is returned to him for labeling . When the ...
346. lappuse
... removing or offering to remove such shipment or delivery or any part thereof from such warehouse unless such batch complies with section 502 ( 1 ) of the act or the cer- tification requirements of section 512 ( n ) of the act or is ...
... removing or offering to remove such shipment or delivery or any part thereof from such warehouse unless such batch complies with section 502 ( 1 ) of the act or the cer- tification requirements of section 512 ( n ) of the act or is ...
347. lappuse
... remove any of such drug from such establishment unless it complies with section 502 ( 1 ) of the act or the cer- tification requirements of of section 512 ( n ) of the act or is so exempt . When the Commissioner finds that such ...
... remove any of such drug from such establishment unless it complies with section 502 ( 1 ) of the act or the cer- tification requirements of of section 512 ( n ) of the act or is so exempt . When the Commissioner finds that such ...
348. lappuse
... remove any of such drug from such es- tablishment unless it complies with section 502 ( 1 ) of the act or the certifi- cation requirements of section 512 ( n ) of the act or is so exempt or is returned to him for labeling or , if ...
... remove any of such drug from such es- tablishment unless it complies with section 502 ( 1 ) of the act or the certifi- cation requirements of section 512 ( n ) of the act or is so exempt or is returned to him for labeling or , if ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning